Sugi Predict

Sugi Predict / Compounds / SCHEMBL173440

SCHEMBL173440

SCHEMBL173440

COC(=O)C1CN(C(=O)OC(C)(C)C)CCC1O

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 3/20 0.47
▸ EPHX1 P07099 1/20 0.46
▸ HPGD P15428 1/20 0.44
▸ ALDH1A1 P00352 3/20 0.43
▸ RECQL P46063 1/20 0.43
▸ PTPN2 P17706 1/20 0.42
▸ PTPN1 P18031 1/20 0.42
▸ PTPN6 P29350 1/20 0.42
▸ MAPT P10636 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ USP2 O75604 1/20 0.41
▸ GPR119 Q8TDV5 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14428295 1.00 PDE4B (0.47) PDE4BEPHX1HPGDALDH1A1RECQL
SCHEMBL14964702 0.88 PDE4B (0.49) PDE4BEPHX1HPGDALDH1A1RECQL
SCHEMBL13390675 0.87 PDE4B (0.48) PDE4BEPHX1HPGDALDH1A1RECQL
SCHEMBL13390607 0.87 PDE4B (0.48) PDE4BEPHX1HPGDALDH1A1RECQL
SCHEMBL13390516 0.87 PDE4B (0.48) PDE4BEPHX1HPGDALDH1A1RECQL
SCHEMBL30453781 0.87 PDE4B (0.48) PDE4BEPHX1HPGDALDH1A1RECQL
SCHEMBL1445046 0.87 PDE4B (0.48) PDE4BEPHX1HPGDALDH1A1RECQL
SCHEMBL8221976 0.87 PDE4B (0.48) PDE4BEPHX1HPGDALDH1A1RECQL
SCHEMBL254627 0.85 HPGD (0.50) EPHX1HPGDALDH1A1RECQLPTPN2
SCHEMBL6218492 0.85 ALDH1A1 (0.46) EPHX1HPGDALDH1A1RECQLMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4559915-A1 PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS Novartis AG (CH) 2025-05-28 — — EP disclosed
US-12312353-B2 Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents NOVARTIS AG (CH) 2025-05-27 — — US disclosed
EP-4013755-B1 PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS NOVARTIS AG (CH) 2025-01-08 — — EP disclosed
US-20230002388-A1 PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) 2023-01-05 — — US disclosed
EP-4081515-A1 INHIBITORS OF MUTANT FORMS OF EGFR Blueprint Medicines Corporation (US) 2022-11-02 — — EP disclosed
CN-115135642-A Inhibitors of mutant forms of EGFR 缆图药品公司 2022-09-30 — — CN disclosed
US-11420970-B1 Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents NOVARTIS AG (CH) 2022-08-23 — — US disclosed
EP-4013755-A1 PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS Novartis AG (CH) 2022-06-22 — — EP disclosed
CN-114585622-A Piperidinyl-methyl-purinamines as NSD2 inhibitors and anticancer agents 诺华股份有限公司 2022-06-03 — — CN disclosed
WO-2021133809-A1 INHIBITORS OF MUTANT FORMS OF EGFR BLUEPRINT MEDICINES CORPORATION (US) 2021-07-01 — — WO disclosed
US-7232909-B2 Pyridine derivatives BAYER AKTIENGESELLSCHAFT (DE) 2007-06-19 — — US disclosed
US-7232909-B2 Pyridine derivatives BAYER AKTIENGESELLSCHAFT (DE) 2007-06-19 — — US disclosed
US-20060205676-A1 Pyridine derivatives BAYER AKTIENGESELLSCHAFT (DE) 2006-09-14 — — US disclosed
US-20060100246-A1 Pyridine derivatives BAYER AKTIENGESELLSCHAFT (DE) 2006-05-11 — — US disclosed
US-6984649-B1 Pyridine derivatives BAYER AKTIENGESELLSCHAFT (DE) 2006-01-10 — — US disclosed
CN-1476442-A Pyridine derivatives with IKB-kinase (IKK-beta) INhibiting activity — 2004-02-18 — — CN disclosed
US-20030216441-A1 Farnesyltransferase inhibitors WEINSTOCK, STEVEN F. 2003-11-20 — — US disclosed
EP-1326856-A1 PYRIDINE DERIVATIVES WITH IKB-KINASE (IKK-BETA) INHIBITING ACTIVITY Bayer Aktiengesellschaft (DE) 2003-07-16 — — EP disclosed
US-6562811-B1 Inhibit I kappa B kinase beta (IKK- beta or IKK-beta) activity, thus inhibit nuclear factor kappa B (NF- kappa B) and can be used for the prophylaxis and treatment of inflammation BAYER AKTIENGESELLSCHAFT (DE) 2003-05-13 — — US disclosed
WO-2002024679-A1 PYRIDINE DERIVATIVES WITH IKB-KINASE (IKK-β) INHIBITING ACTIVITY BAYER AKTIENGESELLSCHAFT (DE) 2002-03-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12312353-B2 Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents NSD2, NSD1, NSD3 PDE4B 1003/4885EPHX1 3646/4885HPGD 1907/4885
US-20060205676-A1 Pyridine derivatives CBR3, ARG1, HRH3 PDE4B 1754/4885EPHX1 3415/4885HPGD 1115/4885
US-11420970-B1 Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents NSD2, NSD1, NSD3 PDE4B 1003/4885EPHX1 3646/4885HPGD 1907/4885
US-20060100246-A1 Pyridine derivatives NAPRT, NNT, NANS PDE4B 276/4885EPHX1 889/4885HPGD 224/4885
US-20030216441-A1 Farnesyltransferase inhibitors FNTA, FNTB, LCAT PDE4B 1233/4885EPHX1 579/4885HPGD 778/4885
US-20230002388-A1 PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS NSD2, NSD1, NSD3 PDE4B 1003/4885EPHX1 3646/4885HPGD 1907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.